Delaware | 0-26224 | 51-0317849 |
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) |
• | supplementing the financial results and forecasts reported to the Company's board of directors; |
• | evaluating, managing and benchmarking the operating performance of the Company; |
• | establishing internal operating budgets; |
• | determining compensation under bonus or other incentive programs; |
• | enhancing comparability from period to period; |
• | comparing performance with internal forecasts and targeted business models; and |
• | evaluating and valuing potential acquisition candidates. |
• | Manufacturing facility remediation costs. These costs represent expenses associated with remediation and related unplanned idle time and underutilization at the Plainsboro, NJ and Añasco, Puerto Rico manufacturing facilities. Management excludes this item when evaluating the Company's operating performance because of the infrequent nature and the magnitude of this item. |
• | Global ERP implementation charges. Systems implementation charges consist of the non-capitalizable portion of internal labor and outside consulting costs related to the implementation of a global ERP system. We have inherited many diverse business processes and different information systems through our numerous acquisitions. Accordingly, we are undertaking this initiative in order to standardize business processes globally and to better integrate all of our existing and acquired operations using one information system. Although recurring in nature given the expected timeframe to complete the implementation for our existing operations and our expectation to continue to acquire new businesses and operations, management excludes these charges when evaluating the operating performance of the Company because the frequency and amount of such charges vary significantly based on the timing and magnitude of the Company's implementation activities. In addition, with the global ERP project continuing the application development phase and entering the testing phase, more costs of the project will be capitalized and, therefore, are not comparable to earlier periods. |
• | Structural optimization charges. These charges, which include employee termination and other costs associated with exit or disposal of facilities, costs related to acquisition integration, costs related to transferring manufacturing and/or distribution activities to different locations, and rationalization or enhancement of our organization, result from rationalizing and enhancing our existing manufacturing, distribution, administrative, functional and commercial infrastructure. Some of these cost-saving and efficiency-driven activities are identified as opportunities in connection with acquisitions that provide the Company with additional capacity or economies of scale. Although recurring in nature given management's ongoing review of the efficiency of our organization and structure, including manufacturing, distribution and administrative facilities and operations, management excludes these items when evaluating the operating performance of the Company because the frequency and amount of such charges vary significantly based on the timing and magnitude of the Company's rationalization activities and are, in some cases, dependent upon opportunities identified in acquisitions, which also vary in frequency and magnitude. |
• | Certain employee termination charges. Certain employee termination and related charges consist of charges related to senior management level terminations and certain significant reductions in force that are not initiated in connection with restructuring. Management excludes these items when evaluating the Company's operating performance because these amounts do not affect our core operations and because of the infrequent and/or large scale nature of these activities. |
• | Acquisition-related charges. Acquisition-related charges include up-front fees and milestone payments that are expensed as incurred in connection with acquiring licenses or rights to technology for which no product has been approved for sale by regulatory authorities and such approval is not reasonably assured at the time such up-front fees or milestone payments are made, inventory fair value purchase accounting adjustments, changes in the fair value of contingent consideration after the acquisition date, and legal, accounting and other outside consultants expenses directly related |
• | Certain expenses associated with product recalls. These costs represent expenses associated with a voluntary recall that happened in the first quarter of 2013 of certain products manufactured in the Añasco, Puerto Rico facility between December 2010 and May 2011 and between November 2012 and March 2013. Management excludes these items when evaluating the Company’s operating performance because of the infrequent and/or large scale nature of these activities. |
• | Impairment charges. The impairment charges category includes impairment charges recorded against various intangible assets such as completed or core technology, customer relationships, tradenames, and in-process research and development previously capitalized in connection with business combinations. Such impairments result primarily from management decisions to discontinue or significantly reduce promoting certain product lines or tradenames, the inability to incorporate existing product technologies into product development programs, and other circumstances. Management excludes this item when evaluating the Company's operating performance because of the infrequent and non-cash nature of this activity. |
• | Intangible asset amortization expense. Management excludes this item when evaluating the Company's operating performance because it is a non-cash expense. |
• | Convertible debt non-cash interest. The convertible debt accounting requires separate accounting for the liability and equity components of the Company's convertible debt instruments, which may be settled in cash upon conversion, in a manner that reflects an applicable non-convertible debt borrowing rate at the time that we issued such convertible debt instruments. Management excludes this item when evaluating the Company's operating performance because of the non-cash nature of the expense. |
• | Income tax impact from adjustments and other items. Estimated impact on income tax expense related to the following: |
(i) | Adjustments to income tax expense for the amount of additional tax expense that the Company estimates that it would record if it used non-GAAP results instead of GAAP results in the calculation of its tax provision, based on the statutory rate applicable to jurisdictions in which the above non-GAAP adjustments relate. |
(ii) | Adjustments to income tax expense in the current quarter for the cumulative impact in that quarter of changes in income tax rates (statutory and estimated effective tax rates) and certain other infrequently occurring items that relate to prior periods. Management excludes these items when evaluating the Company's current quarter operating performance because the cumulative impact in the current quarter of these items applies to prior periods and thus distorts the Company's adjusted income tax rate in the current quarter. The year-to-date adjusted net income and adjusted diluted earnings per share measures are not adjusted by these items, as the cumulative impact is properly reflected in the year-to-date adjusted results. |
• | The Company periodically acquires other companies or businesses, and we expect to continue to incur acquisition-related expenses and charges in the future. These costs can directly impact the amount of the Company's available funds or could include costs for aborted deals which may be significant and reduce GAAP net income. |
• | The Company has initiated a long term effort to implement a global ERP system, and we expect to continue to incur significant systems implementation charges until that effort is completed. These costs can directly impact the amount of the Company's available funds and reduce GAAP net income. |
• | All of the adjustments to GAAP net income have been tax affected at the Company's actual tax rates. Depending on the nature of the adjustments and the tax treatment of the underlying items, the effective tax rate related to adjusted net income could differ significantly from the effective tax rate related to GAAP net income. |
INTEGRA LIFESCIENCES HOLDINGS CORPORATION | ||
Date: May 1, 2014 | By: | /s/ John B. Henneman, III |
John B. Henneman, III | ||
Title: | Corporate Vice President, Finance and Administration, and Chief Financial Officer | |
Exhibit Number | Description of Exhibit |
------------------- | --------------------------- |
99.1 | Press Release with attachments, dated May 1, 2014, issued by Integra LifeSciences Holdings Corporation |
Contacts: | ||||
Integra LifeSciences Holdings Corporation | ||||
John B. Henneman, III | Investor Relations: | |||
Corporate Vice President, | Angela Steinway | |||
Finance and Administration, | (609) 936-2268 | |||
and Chief Financial Officer | angela.steinway@integralife.com | |||
(609) 275-0500 | ||||
Integra LifeSciences Reports First Quarter 2014 Financial Results |
Revenue In Line with Guidance |
Three Months Ended March 31, | |||||||
2014 | 2013 | ||||||
Total revenues | $ | 215,059 | $ | 196,652 | |||
Costs and expenses: | |||||||
Cost of goods sold | 82,383 | 79,612 | |||||
Research and development | 12,567 | 12,716 | |||||
Selling, general and administrative | 108,338 | 102,963 | |||||
Intangible asset amortization | 3,033 | 3,551 | |||||
Total costs and expenses | 206,321 | 198,842 | |||||
Operating income (loss) | 8,738 | (2,190 | ) | ||||
Interest income | 62 | 63 | |||||
Interest expense | (5,142 | ) | (4,800 | ) | |||
Other income (expense), net | 317 | (974 | ) | ||||
Income (loss) before income taxes | 3,975 | (7,901 | ) | ||||
Income tax expense (benefit) | 1,769 | (1,873 | ) | ||||
Net income (loss)* | $ | 2,206 | $ | (6,028 | ) | ||
Diluted net income (loss) per share | $ | 0.07 | $ | (0.22 | ) | ||
Weighted average common shares outstanding for diluted net income (loss) per share | 32,768 | 27,796 |
Three Months Ended March 31, | |||
2014 | 2013 | Change | |
U.S. Neurosurgery | $54,383 | $38,996 | 39% |
U.S. Instruments | 36,720 | 36,948 | (1)% |
U.S. Extremities | 31,912 | 31,361 | 2% |
U.S. Spine & Other | 41,067 | 43,548 | (6)% |
International* | 50,977 | 45,799 | 11% |
Total Revenue | $215,059 | $196,652 | 9% |
Impact of changes in currency exchange rates | $150 | $— | |
Less contribution of revenues from DuraSeal acquisition | (14,220) | — | |
Less contribution of revenues from discontinued products | (2,262) | (3,843) | (41)% |
Total adjusted revenues | $198,727 | $192,809 | 3% |
Item | Total Amount | COGS(a) | SG&A(b) | Amort.(c) | Interest Exp(Inc)(d) | Tax(e) |
Manufacturing facility remediation costs | $143 | $47 | $96 | $— | $— | $— |
Global ERP implementation charges | 6,100 | — | 6,100 | — | — | — |
Structural optimization charges | 2,960 | 1,704 | 1,256 | — | — | — |
Acquisition-related charges | 3,753 | 204 | 3,549 | — | — | — |
Certain employee termination charges | 681 | 322 | 359 | — | — | — |
Intangible asset amortization expense* | 7,433 | 4,400 | — | 3,033 | — | — |
Impairment charges | 600 | 600 | — | — | — | — |
Convertible debt non-cash interest | 1,667 | — | — | — | 1,667 | — |
Estimated income tax impact from adjustments and other items | (6,933) | — | — | — | — | (6,933) |
Depreciation expense | 6,528 | |||||
Stock-based compensation expense | 2,471 |
a) | COGS - Cost of goods sold |
b) | SG&A - Selling, general and administrative |
c) | Amort. - Intangible asset amortization |
d) | Interest (Inc)Exp - Interest (income) expense, net |
e) | Tax - Income tax expense |
Item | Total Amount | COGS (a) | SG&A (b) | Amort. (c) | Interest Exp(Inc) (d) | Tax (e) |
Manufacturing facility remediation costs | $2,125 | $1,843 | $282 | $— | $— | $— |
Certain expenses associated with product recalls | 1,279 | 1,279 | — | — | — | — |
Global ERP implementation charges | 6,149 | — | 6,149 | — | — | — |
Structural optimization charges | 3,408 | 1,061 | 2,347 | — | — | — |
Acquisition-related charges | 388 | 318 | 70 | — | — | — |
Intangible asset amortization expense | 5,204 | 1,653 | — | 3,551 | — | — |
Convertible debt non-cash interest | 1,610 | — | — | — | 1,610 | — |
Estimated income tax impact from adjustments and other items | (5,251) | — | — | — | — | (5,251) |
Depreciation expense* | 5,825 | |||||
Stock-based compensation expense | 2,072 |
a) | COGS - Cost of goods sold |
b) | SG&A - Selling, general and administrative |
c) | Amort. - Intangible asset amortization |
d) | Interest (Inc)Exp - Interest (income) expense, net |
e) | Tax - Income tax expense |
Three Months Ended March 31, | |||||||
2014 | 2013 | ||||||
GAAP net income (loss) | $ | 2,206 | $ | (6,028 | ) | ||
Non-GAAP adjustments: | |||||||
Depreciation and intangible asset amortization expense | 13,961 | 11,029 | |||||
Other (income) expense, net | (317 | ) | 974 | ||||
Interest (income) expense, net | 5,080 | 4,737 | |||||
Income tax expense (benefit) | 1,769 | (1,873 | ) | ||||
Manufacturing facility remediation costs | 143 | 2,125 | |||||
Global ERP implementation charges | 6,100 | 6,149 | |||||
Certain expenses associated with product recalls | — | 1,279 | |||||
Structural optimization charges | 2,960 | 3,408 | |||||
Certain employee termination charges | 681 | — | |||||
Acquisition-related charges | 3,753 | 388 | |||||
Impairment charges | 600 | — | |||||
Total of non-GAAP adjustments | 34,730 | 28,216 | |||||
Adjusted EBITDA | $ | 36,936 | $ | 22,188 | |||
Stock-based compensation | 2,471 | 2,072 | |||||
Adjusted EBITDA excluding stock-based compensation | $ | 39,407 | $ | 24,260 |
Three Months Ended March 31, | |||||||
2014 | 2013 | ||||||
GAAP net income (loss) | $ | 2,206 | $ | (6,028 | ) | ||
Non-GAAP adjustments: | |||||||
Manufacturing facility remediation costs | 143 | 2,125 | |||||
Global ERP implementation charges | 6,100 | 6,149 | |||||
Certain expenses associated with product recalls | — | 1,279 | |||||
Structural optimization charges | 2,960 | 3,408 | |||||
Certain employee termination charges | 681 | — | |||||
Acquisition-related charges | 3,753 | 388 | |||||
Intangible asset amortization expense | 7,433 | 5,204 | |||||
Impairment charges | 600 | — | |||||
Convertible debt non-cash interest | 1,667 | 1,610 | |||||
Estimated income tax impact from adjustments and other items | (6,933 | ) | (5,251 | ) | |||
Total of non-GAAP adjustments | 16,404 | 14,912 | |||||
Adjusted net income | $ | 18,610 | $ | 8,884 | |||
Adjusted diluted net income per share | $0.57 | $0.31 | |||||
Weighted average common shares outstanding for diluted net income (loss) per share | 32,768 | 27,796 | |||||
Non-GAAP adjustment for dilutive effects of equity awards | — | 414 | |||||
Weighted average common shares outstanding for adjusted diluted net income per share | 32,768 | 28,210 |
March 31, 2014 | December 31, 2013 | ||||||
Cash and cash equivalents | $ | 129,038 | $ | 120,614 | |||
Accounts receivable, net | 112,521 | 118,145 | |||||
Inventory, net | 215,232 | 206,919 | |||||
Bank line of credit | 421,875 | 186,875 | |||||
Convertible securities | 207,125 | 205,182 | |||||
Stockholders' equity | 679,200 | 666,090 |
Recorded Year to Date | Projected Year Ended | ||||||||||
March 31, 2014 | December 31, 2014 | ||||||||||
Low | High | ||||||||||
GAAP net income | $ | 2,206 | $ | 37,166 | $ | 43,366 | |||||
Non-GAAP adjustments: | |||||||||||
Manufacturing facility remediation costs | 143 | 143 | 143 | ||||||||
Global ERP implementation charges | 6,100 | 23,100 | 23,100 | ||||||||
Structural optimization charges | 2,960 | 20,800 | 20,800 | ||||||||
Acquisition-related charges | 3,753 | 8,000 | 8,000 | ||||||||
Certain employee termination charges | 681 | 681 | 681 | ||||||||
Intangible asset amortization expense | 7,433 | 30,310 | 30,310 | ||||||||
Impairment charges | 600 | 600 | 600 | ||||||||
Convertible debt non-cash interest | 1,667 | 6,800 | 6,800 | ||||||||
Estimated income tax impact from adjustments and other items | (6,933 | ) | (32,700 | ) | (32,700 | ) | |||||
Total of non-GAAP adjustments | 16,404 | 57,734 | 57,734 | ||||||||
Adjusted net income | $ | 18,610 | $ | 94,900 | $ | 101,100 | |||||
GAAP diluted net income per share | $0.07 | $1.13 | $1.31 | ||||||||
Non-GAAP adjustments detailed above (per share) | $0.50 | $1.75 | $1.75 | ||||||||
Adjusted diluted net income per share | $0.57 | $2.88 | $3.06 | ||||||||
Weighted average common shares outstanding for adjusted diluted net income per share | 32,768 | 33,000 | 33,000 |
Item | Total Amount | COGS | SG&A | Amort. | Interest Exp(Inc) | Tax |
Manufacturing facility remediation costs | $143 | $47 | $96 | $— | $— | $— |
Global ERP implementation charges | 23,100 | — | 23,100 | — | — | — |
Structural optimization charges | 20,800 | 18,500 | 2,300 | — | — | — |
Acquisition-related charges | 8,000 | 1,000 | 7,000 | — | — | — |
Certain employee termination charges | 681 | 322 | 359 | — | — | — |
Intangible asset amortization expense | 30,310 | 18,360 | — | 11,950 | — | — |
Impairment charges | 600 | 600 | — | — | — | — |
Convertible debt non-cash interest | 6,800 | — | — | — | 6,800 | — |
Estimated income tax impact from adjustments and other items | (32,700) | — | — | — | — | (32,700) |